NCT04822337 2026-04-16
Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma
Wake Forest University Health Sciences
Phase 1/2 Active not recruiting
Clinical Trials
8 trialsNCT05280275 2023-12-01
A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Transplant Ineligible
Hellenic Society of Hematology
Phase 1/2 Unknown
NCT05573802 2023-10-24
A Study to Investigate Safety and Clinical Activity of Belantamab Mafodotin in Combination With Lenalidomide, Dexamethasone and Nirogacestat in Patients With Transplant Ineligible Newly Diagnosed Multiple Myeloma
Hellenic Society of Hematology
Phase 1/2 Recruiting
NCT00477750 2019-10-11
Melphalan, Prednisone, and Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma
Mayo Clinic
Phase 1/2 Completed
NCT00790842 2018-10-24
PrE1003
PrECOG, LLC.
Phase 1/2 Terminated
NCT01079936 2016-06-06
Lenalidomide and High-Dose Melphalan
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT01531998 2015-06-19
Lenalidomide/Bortezomib/Dexamethasone & CNTO 328 in Transplant Eligible Newly Diagnosed Multiple Myeloma (MM)
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT01002703 2011-08-12
Treatment With Lenalidomide, Bendamustine and Prednisone (RBP) in Patients With Relapsed or Refractory Multiple Myeloma
University of Leipzig
Phase 1/2 Unknown